HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Mackie
Fiona E
FE
Sydney Children's Hospital Randwick, New South Wales, NSW, Australia. f.mackie@unsw.edu.au
Rosenberg
Andrew R
AR
Harmer
Jason A
JA
Kainer
Gad
G
Celermajer
David S
DS
D000293:Adolescent; D000069059:Atorvastatin; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D010865:Pilot Projects; D011446:Prospective Studies; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin